Physician profile
Antonio Santillan-Gomez
NPI 1013055813
$162,128.40
in general payments reported to CMS, 2019-2025
38 companies · $12K in 2025
The $12K reported for 2025 was more than what 92% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $13K · 2021: $14K · 2022: $29K · 2023: $32K · 2024: $26K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $32K · Education: $11K · Consulting Fee: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,000 · Food and Beverage: $5,172 · Travel and Lodging: $4,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $31,850.00 |
| Education | $11,307.65 |
| Consulting Fee | $10,147.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,000.00 |
| Food and Beverage | $5,172.04 |
| Travel and Lodging | $4,800.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $61,026.76 | 2019-2025 | Da Vinci Surgical System |
| Myriad Genetic Laboratories, INC. | $58,390.92 | 2020-2025 | Precisetumor, Myrisk, Mychoice Cdx |
| Medical Device Business Services, INC. | $28,157.72 | 2019-2022 | |
| Baxter Healthcare | $4,966.08 | 2024-2025 | Tisseel, Seprafilm, Adept |
| Astrazeneca Pharmaceuticals Lp | $4,475.11 | 2019-2025 | Lynparza |
| Aspira Women'S Health INC | $1,849.49 | 2019-2020 | |
| Ethicon INC. | $757.50 | 2020 | |
| Ethicon US, LLC | $312.04 | 2019-2022 | |
| Clovis Oncology, INC. | $227.88 | 2019-2020 | |
| Abbvie INC. | $224.97 | 2019-2025 | |
| Amgen INC. | $220.00 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $215.79 | 2019-2022 | |
| Eisai INC. | $163.24 | 2023-2024 | |
| Momentis Surgical INC. | $157.42 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2023 | Uptravi, Opsumit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $105.49 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.99 | 2019 | |
| Seagen INC. | $96.44 | 2023-2025 | Tivdak |
| Merck Sharp & Dohme LLC | $82.43 | 2019-2024 | Keytruda |
| Conmed Corporation | $79.75 | 2022-2025 | Visiclear, Abc Handpieces, Vcare |
| Hologic Sales and Service, LLC | $72.71 | 2022-2025 | Thinprep 2000 Processor, Myosure Tissue Removal Device, Novasure |
| Puma Biotechnology, INC. | $57.21 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $40.49 | 2019 | |
| Tactile Systems Technology INC | $33.35 | 2025 | Flexitouch Plus, Nimbl |
| Novartis Pharmaceuticals Corporation | $32.11 | 2019 | |
| Tesaro, INC. | $24.03 | 2019 | |
| Meditrina | $18.47 | 2025 | |
| Genzyme Corporation | $17.99 | 2019 | |
| Sobi, INC | $17.68 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $17.50 | 2019 | |
| Incyte Corporation | $15.83 | 2019 | |
| Covidien Lp | $15.15 | 2019 | |
| Pfizer INC. | $14.74 | 2024 | |
| Exelixis INC. | $13.82 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $3.31 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Santillan-Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.